Check out the latest features and columns!

Pharmaceutical Executive December 2022

December's Executive Profile features Kimberly Moran, head of rare diseases in the US for UCB

Business and Passion

Pharm Exec's 18th Annual Pipeline Report focuses on spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics

Capitalizing on Opportunity

Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences stakeholders

Whole-Person Care: Are We Ready? The Intersection of Pharma and Digital Therapeutics

Pharm Exec profiles its 2022 Emerging Pharma Leaders

Pharm Exec's 2022 Emerging Pharma Leaders

Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

Current virus “triple whammy” taxes supply levels, while raising concerns over FDA’s limited power to track drug demand spikes.

Rising Demand Drives Drug Shortages

The International Federation of Pharmaceutical Manufacturers and Associations commissioned Ipsos to perform the research.

Research Shows Improvement In Research-Based Pharma Industry Reputation

 and can be reached at fpollaro@mjhlifesciences.com.

Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?

Biopharma’s Untapped Value: The Quest to Reverse First-Launch Failure Trends

Mike Straus is a freelance writer based in British Columbia, Canada. His work has appeared in 

Nutritional Outlook, Hoist, and Massage Therapy Canada

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

2023 Pipeline Report: Testing the Limits

 and can be reached at mhollan@mjhlifesciences.com.

Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.

Will biopharma investment heat up and signal better fortunes for 2023? 

Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conference

Whether pharma or FDA, healthcare outreach more visible than ever.

Aligning Trust and Transparency in Brand Messaging

Companies should search within to gain talent edge.

Pharma Needs to Look Internally for New Leadership

No shortage of views being expressed on drug shortages.

Seeking Concrete Solutions to Europe’s Supply Problems

Year characterized by mix of key advances, contentious stances.

Featured Content

Pharmaceutical Executive December 2022

Business and Passion

Capitalizing on Opportunity

Whole-Person Care: Are We Ready? The Intersection of Pharma and Digital Therapeutics

Pharm Exec's 2022 Emerging Pharma Leaders